T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity.
T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
Company Details
- Employees
- 84
- Founded
- -
- Address
- San Francisco, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- t-knife.com
- Keywords
- immunoncology, tumor immunology, T cell receptor, adoptive T cell therapy, cell therapy, gene therapy, TCR gene transfer, TCR generation, TCR characterization, cancer testis antigens, tumor antigens, target selection, retroviral vectors, neoepitopes, neoantigens, gene therapy.
- HQ
- San Francisco
T-Knife Therapeutics Questions
T-Knife Therapeutics's website is t-knife.com
T-Knife Therapeutics's LinkedIn profile is https://www.linkedin.com/company/t-knife
T-Knife Therapeutics has
84 employees.
View email and phone details for 84
employees at T-Knife Therapeutics.
T-Knife Therapeutics's industry is
Biotechnology Research
T-Knife Therapeutics's top competitors are
Glycostem Therapeutics,
Adaptimmune,
Medigene Ag,
Omeicos Therapeutics Gmbh,
Captain T Cell,
Zelluna,
Immatics,
Nykode Therapeutics,
Kite Pharma,
Celyad Oncology.
T-Knife Therapeutics's categories are Biotechnology Research
T-Knife Therapeutics's founding year is 2018
